Pethidine

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Script error: No such module "about". Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Pethidine
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesDemerol, others
Other namesTemplate:Infobox drug/localINNvariants
Pregnancy
category		Page Template:Plainlist/styles.css has no content.
  • AU: C
Dependence
liability		High
Addiction
liability		High[1]
Routes of
administration		By mouth, intravenous, intramuscular, intrathecal,[2] subcutaneous, epidural[3]
Drug classOpioid
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Bioavailability50–60% (Oral), 80–90% (Oral, in cases of hepatic impairment)
Protein binding65–75%
MetabolismLiver: CYP2B6, CYP3A4, CYP2C19, Carboxylesterase 1
Metabolites
Elimination half-life2.5–4 hours, 7–11 hours (liver disease)
ExcretionRenal
Identifiers
  • Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC15H21NO2
Molar mass247.338 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CCOC(=O)C1(c2ccccc2)CCN(C)CC1
  • InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3 checkY
  • Key:XADCESSVHJOZHK-UHFFFAOYSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Pethidine, also known as meperidine and sold under the brand name Demerol among others, is a fully synthetic opioid pain medication of the phenylpiperidine class.[5][6][7][8][9][10] Synthesized in 1938[11] as a potential anticholinergic agent by the German chemist Otto Eisleb, its analgesic properties were first recognized by Otto Schaumann while working for IG Farben, in Germany.[12] Pethidine is the prototype of a large family of analgesics including the pethidine 4-phenylpiperidines (e.g., piminodine, anileridine), the prodines (e.g., alphaprodine, MPPP), bemidones (e.g., ketobemidone), and others more distant, including diphenoxylate and analogues.[13]

Pethidine is indicated for the treatment of moderate to severe pain, and is delivered as a hydrochloride salt in tablets, as a syrup, or by intramuscular, subcutaneous, or intravenous injection. For much of the 20th century, pethidine was the opioid of choice for many physicians; in 1975, 60% of doctors prescribed it for acute pain and 22% for chronic severe pain.[14]

It was patented in 1937 and approved for medical use in 1943.[15] Compared with morphine, pethidine was considered to be safer, carry a lower risk of addiction, and to be superior in treating the pain associated with biliary spasm or renal colic due to its assumed anticholinergic effects.[7] These were later discovered to be inaccurate assumptions, as it carries an equal risk of addiction and possesses no advantageous effects on biliary spasm or renal colic compared to other opioids. Due to the neurotoxicity of its metabolite, norpethidine, it is more toxic than other opioids—especially during long-term use.[7] The norpethidine metabolite was found to have serotonergic effects, so pethidine could, unlike most opioids, increase the risk of triggering serotonin syndrome.[7][8]

Medical uses

Pethidine is the most widely used opioid in labour and delivery.[16] It has fallen out of favour in some countries, such as the United States, in favour of other opioids, due to its potential drug interactions, especially with serotonergics, and its neurotoxic metabolite, norpethidine.[10] It is still commonly used in the United Kingdom and New Zealand,[17] and was the preferred opioid in the United Kingdom for use during labour, but has been superseded somewhat by other strong semi-synthetic opioids (e.g. hydromorphone) to avoid serotonin interactions since the mid-2000s.[18]

Pethidine is the preferred painkiller for diverticulitis, because it decreases intestinal intraluminal pressure.[19][full citation needed] Pethidine is the preferred drug for the management of shivering during therapeutic hypothermia, as it provides the greatest reduction in the shivering threshold.[20]

Before 2003, it was on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[21][22]

Adverse effects

The adverse effects of pethidine administration are primarily those of the opioids as a class: nausea, vomiting, dizziness, diaphoresis, urinary retention, and constipation. Due to moderate stimulant effects mediated by pethidine's dopamine and norepinephrine reuptake inhibition, sedation is less likely compared to other opioids. Unlike other opioids, it does not cause miosis because of its anticholinergic properties. Overdose can cause muscle flaccidity, respiratory depression, obtundation, psychosis, cold and clammy skin, hypotension, and coma.[23][24]

A narcotic antagonist such as naloxone is indicated to reverse respiratory depression and other effects of pethidine. Serotonin syndrome has occurred in patients receiving concurrent antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors, or other medication types (see Interactions below). Convulsive seizures sometimes observed in patients receiving parenteral pethidine on a chronic basis have been attributed to accumulation in plasma of the metabolite norpethidine (normeperidine). Fatalities have occurred following either oral or intravenous pethidine overdose.[25][26]

Interactions

Pethidine has serious interactions that can be dangerous with monoamine oxidase inhibitors (e.g., furazolidone, isocarboxazid, moclobemide, phenelzine, procarbazine, selegiline, tranylcypromine). Such patients may suffer agitation, delirium, headache, convulsions, and/or hyperthermia. Fatal interactions have been reported including the death of Libby Zion.[27]

Seizures may develop when tramadol is given intravenously following, or with, pethidine.[28] It can interact as well with SSRIs and other antidepressants, antiparkinson agents, migraine therapy, stimulants and other agents causing serotonin syndrome. It is thought to be caused by an increase in cerebral serotonin concentrations. It is probable that pethidine can also interact with a number of other medications, including muscle relaxants, benzodiazepines, and ethanol.

Mechanism of action

Script error: No such module "Labelled list hatnote".

Like morphine, pethidine exerts its analgesic effects by acting as an agonist at the μ-opioid receptor.[29]

Pethidine is often employed in the treatment of postanesthetic shivering. The pharmacologic mechanism of this antishivering effect is not fully understood,[30] but it may involve the stimulation of κ-opioid receptors.[31]

Pethidine has structural similarities to atropine and other tropane alkaloids and may have some of their effects and side effects.[32] In addition to these opioidergic and anticholinergic effects, it has local anesthetic activity related to its interactions with sodium ion channels.

Pethidine's apparent in vitro efficacy as an antispasmodic agent is due to its local anesthetic effects. It does not have antispasmodic effects in vivo.[33] Pethidine also has stimulant effects mediated by its inhibition of the dopamine transporter (DAT) and norepinephrine transporter (NET). Pethidine will substitute for cocaine in animals trained to discriminate cocaine from saline, probably as a result of its inhibitory actions on DAT and NET.[34]

Several analogs of pethidine such as 4-fluoropethidine have been synthesized that are potent inhibitors of the reuptake of the monoamine neurotransmitters dopamine and norepinephrine via DAT and NET.[35][36] It has also been associated with cases of serotonin syndrome, suggesting some interaction with serotonergic neurons, but the relationship has not been definitively demonstrated.[34][36][37][38]

It is more lipid-soluble than morphine, resulting in a faster onset of action. Its duration of clinical effect is 120–150 minutes, although it is typically administered at 4– to 6-hour intervals. Pethidine has been shown to be less effective than morphine, diamorphine, or hydromorphone at easing severe pain, or pain associated with movement or coughing.[34][36][38]

Like other opioid drugs, pethidine has the potential to cause physical dependence or addiction. The especially severe side effects unique to pethidine among opioids—serotonin syndrome, seizures, delirium, dysphoria, tremor—are primarily or entirely due to the action of its metabolite, norpethidine.[36][38]

Pharmacology

Pharmacodynamics

Pethidine has weak binding affinity for the mu-opioid receptor in humans at 450.1 nM (Morphine 1.168).[39]

Pharmacokinetics

File:Pethidine DOJ.jpg

Pethidine is quickly hydrolysed in the liver to pethidinic acid and is also demethylated to norpethidine, which has half the analgesic activity of pethidine but a longer elimination half-life (8–12 hours);[40] accumulating with regular administration, or in kidney failure. Norpethidine is toxic and has convulsant and hallucinogenic effects.[unreliable medical source?]

The toxic effects mediated by the metabolites cannot be countered with opioid receptor antagonists such as naloxone or naltrexone, and are probably primarily due to norpethidine's anticholinergic activity probably due to its structural similarity to atropine, though its pharmacology has not been thoroughly explored. The neurotoxicity of pethidine's metabolites is a unique feature of pethidine compared to other opioids. Pethidine's metabolites are further conjugated with glucuronic acid and excreted into the urine.[unreliable medical source?]

File:Metabolism of pethidine.png

Recreational use

In data from the U.S. Drug Abuse Warning Network, mentions of hazardous or harmful use of pethidine declined between 1997 and 2002, in contrast to increases for fentanyl, hydromorphone, morphine, and oxycodone.[41] The number of dosage units of pethidine reported lost or stolen in the U.S. increased 16.2% between 2000 and 2003, from 32,447 to 37,687.[42]

Synthesis

Pethidine can be produced in a two-step synthesis. The first step is reaction of benzyl cyanide and chlormethine in the presence of sodium amide to form a piperidine ring. The nitrile is then converted to an ester.[43]

File:Pethidine synthesis.PNG
Pethidine synthesis

Control

Pethidine is in Schedule II of the Controlled Substances Act 1970 of the United States as a Narcotic with ACSCN 9230 with a 6250 kilo aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.87 for the hydrochloride and 0.84 for the hydrobromide. The A, B, and C intermediates in production of pethidine are also controlled, with ACSCN being 9232 for A (with a 6 gram quota) and 9233 being B (quota of 11 grams) and 9234 being C (6 gram quota).[44] It is listed under the Single Convention for the Control of Narcotic Substances 1961 and is controlled in most countries in the same fashion as is morphine.[citation needed]

Veterinary use

Pethidine provides analgesia for 60 to 90 minutes in the cat and dog.[39] Pethidine is less effective in horses, with IV, SC, and IM administration failing to provide thermal antinociception.[39][45][46] Epidural administration of pethidine into the caudal area provided 4-5 hours of analgesia with no cardiovascular depression and only minor sedation.[47][39] Due to the short duration of analgesia and side effects pethidine is not commonly used with other opioids being used instead.[48]

Pethidine is vagolytic but high doses cause bradycardia due to cardiac depression. Pethidine is metabolised by the hepatic enzyme CYP450 via N-demethylation to produce normeperidine. Normeperidine is excitotoxic and can cause myoclonus when too much pethidine is administered. The treatment for these side effects are benzodiazepines. Histamine release following IV administration can cause flare reaction, pruritus, hypersalivation, urination, defaecation, and tachypnoea. IM injection can cause localised oedema and erythema.[39]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN 978-1-4557-0150-6. Archived from the original on 10 January 2023. Retrieved 20 August 2019.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Ngan Kee WD (April 1998). "Intrathecal pethidine: pharmacology and clinical applications". Anaesthesia and Intensive Care. 26 (2): 137–146. doi:10.1177/0310057X9802600202. PMID 9564390.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Ngan Kee WD (June 1998). "Epidural pethidine: pharmacology and clinical experience". Anaesthesia and Intensive Care. 26 (3): 247–255. doi:10.1177/0310057X9802600303. PMID 9619217.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in português do Brasil). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Demerol, Pethidine (meperidine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 9 April 2014.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Shipton E (March 2006). "Should New Zealand continue signing up to the Pethidine Protocol?" (PDF). The New Zealand Medical Journal. 119 (1230): U1875. PMID 16532042. Archived from the original (PDF) on 2014-04-08.
  7. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Latta KS, Ginsberg B, Barkin RL (January–February 2002). "Meperidine: a critical review". American Journal of Therapeutics. 9 (1): 53–68. doi:10.1097/00045391-200201000-00010. PMID 11782820. S2CID 23410891.
  8. ^ a b Page Module:Citation/CS1/styles.css has no content.MacPherson RD, Duguid MD (2008). "Strategy to Eliminate Pethidine Use in Hospitals". Journal of Pharmacy Practice and Research. 38 (2): 88–89. doi:10.1002/j.2055-2335.2008.tb00807.x. S2CID 71812645.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Mather LE, Meffin PJ (September–October 1978). "Clinical pharmacokinetics of pethidine". Clinical Pharmacokinetics. 3 (5): 352–368. doi:10.2165/00003088-197803050-00002. PMID 359212. S2CID 35402662.
  10. ^ a b Page Module:Citation/CS1/styles.css has no content.Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  11. ^ US 2167351 Piperidine compounds and a process of preparing them
  12. ^ Page Module:Citation/CS1/styles.css has no content.Michaelis M, Schölkens B, Rudolphi K (April 2007). "An anthology from Naunyn-Schmiedeberg's archives of pharmacology". Naunyn-Schmiedeberg's Archives of Pharmacology. 375 (2): 81–84. doi:10.1007/s00210-007-0136-z. PMID 17310263. S2CID 27774155.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Reynolds AK, Randall LO (1957). Morphine and Allied Drugs. Toronto/London: University of Toronto Press/Oxford University Press. pp. 273–319.
  14. ^ Page Module:Citation/CS1/styles.css has no content.Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, et al. (February 1983). "Central nervous system excitatory effects of meperidine in cancer patients". Annals of Neurology. 13 (2): 180–185. doi:10.1002/ana.410130213. PMID 6187275. S2CID 44353966.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 52X. ISBN 978-3-527-60749-5.
  16. ^ Page Module:Citation/CS1/styles.css has no content.Bricker L, Lavender T (May 2002). "Parenteral opioids for labor pain relief: a systematic review". American Journal of Obstetrics and Gynecology. 186 (5 Suppl Nature): S94–109. doi:10.1016/S0002-9378(02)70185-3. PMID 12011876.
  17. ^ Page Module:Citation/CS1/styles.css has no content."Parenteral opioids for maternal pain relief in labour". World Health Organization. Archived from the original on June 20, 2015. Retrieved 2015-06-20.
  18. ^ Page Module:Citation/CS1/styles.css has no content."Pain relief in labour – Pregnancy and baby guide". NHS Choices. Archived from the original on 2015-06-12. Retrieved 2015-06-20.
  19. ^ Blueprints – Family Medicine (3rd edition)
  20. ^ Page Module:Citation/CS1/styles.css has no content.Logan A, Sangkachand P, Funk M (December 2011). "Optimal management of shivering during therapeutic hypothermia after cardiac arrest". Critical Care Nurse. 31 (6): e18–30. doi:10.4037/ccn2011618. PMID 22135340.
  21. ^ Page Module:Citation/CS1/styles.css has no content."Essential Medicines WHO Model List (revised April 2002)" (PDF) (12th ed.). Geneva, Switzerland: World Health Organization. April 2002. Retrieved 6 September 2017.
  22. ^ Page Module:Citation/CS1/styles.css has no content."Essential Medicines WHO Model List (revised April 2003)" (PDF) (13th ed.). Geneva, Switzerland: World Health Organization. April 2003. Retrieved 6 September 2017.
  23. ^ Page Module:Citation/CS1/styles.css has no content.Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 911–914.
  24. ^ Page Module:Citation/CS1/styles.css has no content."Package insert for meperidine hydrochloride" (PDF). Ridgefield, CT: Boehringer Ingelheim. 2005.
  25. ^ Page Module:Citation/CS1/styles.css has no content.Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 911–914.
  26. ^ Page Module:Citation/CS1/styles.css has no content."Package insert for meperidine hydrochloride" (PDF). Ridgefield, CT: Boehringer Ingelheim. 2005.
  27. ^ Page Module:Citation/CS1/styles.css has no content.Brody J (February 27, 2007). "A Mix of Medicines That Can Be Lethal". New York Times. Retrieved 2009-02-13.
  28. ^ Page Module:Citation/CS1/styles.css has no content."Serious Reactions with Tramadol: Seizures and Serotonin Syndrome". medsafe.govt.nz (Prescriber Update 28(1) ed.). New Zealand Pharmacovigilance Centre, Dunedin: New Zealand Medicines and Medical Devices Safety Authority. October 2007. Retrieved 7 November 2019.
  29. ^ Page Module:Citation/CS1/styles.css has no content.Bryant B, Knights K (2010). Pharmacology for Health Professionals (3rd ed.). Chatswood: Mosby Australia. ISBN 978-0-7295-3929-6.
  30. ^ Page Module:Citation/CS1/styles.css has no content.Koczmara C, Perri D, Hyland S, Rousseaux L (2005). "Meperidine (Demerol) safety issues" (PDF). Dynamics. 16 (1): 8–12. PMID 15835452. Retrieved 2014-01-11.
  31. ^ Page Module:Citation/CS1/styles.css has no content.Laurence B (2010). Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). McGraw-Hill. p. 549. ISBN 978-0-07-162442-8.
  32. ^ Page Module:Citation/CS1/styles.css has no content."Petidin Meda - FASS Vårdpersonal".
  33. ^ Page Module:Citation/CS1/styles.css has no content.Wagner LE, Eaton M, Sabnis SS, Gingrich KJ (November 1999). "Meperidine and lidocaine block of recombinant voltage-dependent Na+ channels: evidence that meperidine is a local anesthetic". Anesthesiology. 91 (5): 1481–1490. doi:10.1097/00000542-199911000-00042. PMID 10551601. S2CID 34806974.
  34. ^ a b c Page Module:Citation/CS1/styles.css has no content.Izenwasser S, Newman AH, Cox BM, Katz JL (February 1996). "The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter". European Journal of Pharmacology. 297 (1–2): 9–17. doi:10.1016/0014-2999(95)00696-6. PMID 8851160.
  35. ^ Page Module:Citation/CS1/styles.css has no content.Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, et al. (March 2005). "Synthesis and biological evaluation of meperidine analogues at monoamine transporters". Journal of Medicinal Chemistry. 48 (5): 1336–1343. doi:10.1021/jm0401614. PMID 15743177.
  36. ^ a b c d Page Module:Citation/CS1/styles.css has no content."Demerol: Is It the Best Analgesic?" (PDF), Pennsylvania Patient Safety Reporting Service Patient Safety Advisory, 3 (2), June 2006, archived from the original (PDF) on 2013-06-20, retrieved 2013-04-15
  37. ^ Page Module:Citation/CS1/styles.css has no content.Davis S (August 2004). "Use of pethidine for pain management in the emergency department: a position statement of the NSW Therapeutic Advisory Group" (PDF). New South Wales Therapeutic Advisory Group. Archived from the original (PDF) on 2006-10-09. Retrieved 2007-01-17.
  38. ^ a b c Page Module:Citation/CS1/styles.css has no content.Latta KS, Ginsberg B, Barkin RL (January–February 2002). "Meperidine: a critical review". American Journal of Therapeutics. 9 (1): 53–68. doi:10.1097/00045391-200201000-00010. PMID 11782820. S2CID 23410891.
  39. ^ a b c d e Page Module:Citation/CS1/styles.css has no content.Simon BT, Lizarraga I (11 September 2024). "Opioids". In Lamont L, Grimm K, Robertson S, Love L, Schroeder C (eds.). Veterinary Anesthesia and Analgesia, The 6th Edition of Lumb and Jones. Wiley Blackwell. pp. 378–379. ISBN 978-1-119-83027-6.
  40. ^ Page Module:Citation/CS1/styles.css has no content.Molloy A (2002). "Does pethidine still have a place in therapy?". Australian Prescriber. 25 (1): 12–13. doi:10.18773/austprescr.2002.008.
  41. ^ Page Module:Citation/CS1/styles.css has no content.Gilson AM, Ryan KM, Joranson DE, Dahl JL (August 2004). "A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002". Journal of Pain and Symptom Management. 28 (2): 176–188. CiteSeerX 10.1.1.387.1900. doi:10.1016/j.jpainsymman.2004.01.003. PMID 15276196.
  42. ^ Page Module:Citation/CS1/styles.css has no content.Joranson DE, Gilson AM (October 2005). "Drug crime is a source of abused pain medications in the United States". Journal of Pain and Symptom Management. 30 (4): 299–301. doi:10.1016/j.jpainsymman.2005.09.001. PMID 16256890.
  43. ^ Patent Appl. DE 679 281 IG Farben 1937.
  44. ^ Page Module:Citation/CS1/styles.css has no content."Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014". Archived from the original on 2016-03-04. Retrieved 2016-02-26.
  45. ^ Page Module:Citation/CS1/styles.css has no content.Hanafi AL, Reed RA, Trenholme HN, Sakai DM, Ryan CA, Barletta M, et al. (February 2021). "Pharmacokinetics and pharmacodynamics of meperidine after intramuscular and subcutaneous administration in horses". Veterinary Surgery. 50 (2): 410–417. doi:10.1111/vsu.13545. PMID 33242227.
  46. ^ Page Module:Citation/CS1/styles.css has no content.Hamamoto-Hardman BD, Steffey EP, McKemie DS, Kass PH, Knych HK (October 2020). "Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses". BMC Veterinary Research. 16 (1): 368. doi:10.1186/s12917-020-02564-4. PMC 7528573. PMID 32998730.
  47. ^ Page Module:Citation/CS1/styles.css has no content.Skarda RT, Muir WW (July 2001). "Analgesic, hemodynamic, and respiratory effects induced by caudal epidural administration of meperidine hydrochloride in mares". American Journal of Veterinary Research. 62 (7): 1001–1007. doi:10.2460/ajvr.2001.62.1001. PMID 11453471.
  48. ^ Page Module:Citation/CS1/styles.css has no content.Papich M (2016). Saunders Handbook of Veterinary Drugs (4th ed.). Elsevier. ISBN 978-0-323-24485-5.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Template:Ionotropic glutamate receptor modulators Template:Monoamine reuptake inhibitors Template:Muscarinic acetylcholine receptor modulators Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Pethidine&oldid=372373"